Vertex Pharmaceuticals (VRTX) offered an upbeat outlook Tuesday for its bread-and-butter cystic fibrosis medicines, but VRTX stock fell on sales that just met forecasts. X During the December quarter,...
Tag: VRTX
NASDAQ Stocks For The Santa Claus Rally
AP Photo/Yorgos Karahalis Copyright 2022 The Associated Press. All rights reserved. The overall market is expected to move higher from December 15th through January 7-11. Seasonally this has been one ...
VRTX Stock Reverses Higher On Third-Quarter Beat After Regular-Session Tumble
Vertex Pharmaceuticals (VRTX) beat third-quarter expectations Thursday, helping VRTX stock shrug off some of the malaise that plagued it during the regular session. X In after-hours trading on today&#...
Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market
Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street ...
Chevron, Micron and 18 More Stocks Goldman Recommends to Ride Out the Storm
Text size Qualcomm is one of the 20 stocks on Goldman Sachs’ ‘margin of safety’ list. Pau Barrena /AFP via Getty Images Exxon Mobil , Qualcomm , Micron and Chevron are just some of t...
VRTX Stock: Biotech Offers Bullish 2022 View After Quarterly Beat
Vertex Pharmaceuticals (VRTX) issued a bullish 2022 outlook Thursday, leading VRTX stock to approach a 12-month high. X The company expects its cystic fibrosis treatments to generate $8.4 billion to $...
Biotech Stocks Are Due to Bounce Back. This One Stands Out.
Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have stock-market capitalizations that are smaller th...